Correlation Engine 2.0
Clear Search sequence regions


  • humans (1)
  • kinases (2)
  • mTOR (7)
  • mtor protein (1)
  • organ (3)
  • patients (2)
  • protein human (1)
  • sirolimus (2)
  • Sizes of these terms reflect their relevance to your search.

    mTOR inhibitors possess narrow therapeutic range and substantial pharmacokinetic variability and the consequences from suboptimal dosing are serious. The aim of this review is to summarize the current knowledge about the factors influencing mTOR inhibitors pharmacokinetics and the possibility of using these relationships in order to improve its therapy individualization in solid organ transplanted patients. Literature search from Pubmed and Web of Science databases were performed using Boolean search operators in order to identify relevant studies. A total of 701 reports were identified from the initial literature search. Out of which 40 studies dealt with relationships between various factors and pharmacokinetics of mTOR inhibitors and with relevance of these associations for dosage optimization. The overview of the current covariates for pharmacokinetic variability of mTOR inhibitors has been provided on the level of absorption, distribution and elimination, and consequences of these relationships for dosing optimization has been summarized. © 2022 John Wiley & Sons Ltd.

    Citation

    Jan Miroslav Hartinger, Pavel Ryšánek, Ondřej Slanař, Martin Šíma. Pharmacokinetic principles of dose adjustment of mTOR inhibitors in solid organ transplanted patients. Journal of clinical pharmacy and therapeutics. 2022 Sep;47(9):1362-1367

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 35934622

    View Full Text